Oncology Power Hour: Recent Episodes

View Details

Guest: James G. Christensen, MD

Catch up on how new research presented at the 2021 ESMO Congress is helping to evolve targeted therapies for colorectal and pancreatic cancer with Dr. James G. Christensen.

View Details

Guest: Edward B. Garon, MD

Could a new standard of treatment be on the horizon for patients with HER2 mutated NSCLC? Dr. Edward Garon, a Thoracic Medical Oncologist at UCLA Health, shares key takeaways on non-small cell lung cancer from the ESMO 2021 Congress.

View Details

Host: Jennifer Caudle, DO

Guest: Tracey Evans, MD

Join Dr. Tracey Evans as she discusses the efficacy data for TAGRISSO® (osimertinib) and the potential impact for metastatic EGFRm NSCLC patients.

In 2018, first-line TAGRISSO became a standard of care for metastatic EGFRm NSCLC with an unprecedented 18.9 months median PFS vs 10.2 months for erlotinib/gefitinib (HR=0.46 [95% CI: 0.37, 0.57]; P<0.0001).1

Now, TAGRISSO is the only EGFR TKI to deliver statistically significant Overall Survival beyond 3 years in a global, phase 3 randomized clinical trial in the first-line setting, (38.6 months vs 31.8 months for erlotinib/gefitinib (HR=0.799 [95.05% CI: 0.641, 0.997]; P=0.0462)).2

Visit TagrissoHCP.com to learn what these data could mean for your patients.

FLAURA study design: Randomized, double-blind, active-controlled trial in 556 patients with metastatic EGFRm NSCLC who had not received prior systemic treatment for advanced disease. Patients were randomized 1:1 to either TAGRISSO (n=279; 80 mg orally, once daily) or EGFR-TKI comparator (n=277; gefitinib 250 mg or erlotinib 150 mg orally, once daily). All US patients in the comparator arm received erlotinib. Crossover was allowed for patients in the EGFR-TKI comparator arm at confirmed progression if positive for the EGFR T790M resistance mutation. Patients with CNS metastases not requiring …

View Details

Guest: Jason Day

Guest: Dening Day

Biomarker testing is a critical step in any mNSCLC patient’s treatment journey, as PGA champion Jason Day found out when his mother, Dening, was diagnosed with the disease.1-3

In this video, Jason and Dening tell their story about how biomarker testing helped Dening get on a therapy that can target the driver of her disease. Jason and Dening’s story may help your newly diagnosed mNSCLC patients understand the importance of testing their lung cancer, knowing the full molecular results, and treating based on those results.

Share this video and more with your patients by visiting TestLungCancer.com.

References:

1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC V.3.2020. ©National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed February 11, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
2. Brahmer JR, Govindan R, Anders RA, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J …

View Details

Host: Chrysalyne D. Schmults, MD, MSCE (Chair)

Guest: Omid Hamid, MD

Guest: Anokhi Jambusaria, MD, MSCE, FAAD

Please note: This activity is no longer available for continuing education credit.

The recent approval of the first immunotherapeutic agent for cutaneous squamous cell carcinoma (cSCC) is changing the way healthcare providers treat patients with inoperable cSCC. In this roundtable discussion, a cSCC survivor draws upon his experience with the cancer when surgery and chemotherapy failed him, as our multidisciplinary faculty panel focus on how to optimally select patients with cSCC for treatment with immunotherapy.

View Details

Host: Maurice Pickard, MD

Guest: Olufunmilayo (Funmi) Olopade, MD, FACP

Host Dr. Maurice Pickard welcomes Dr. Funmi Olopade, Walter L. Palmer Distinguished Service Professor in Medicine and Human Genetics, Director of the Hematology/Oncology Fellowship Program, and Director of the Center for Clinical Cancer Genetics at the University of Chicago. Dr. Olopade discusses disparities in health outcomes for black women with breast cancer. Dr. Olopade is an expert in cancer risk assessment and individualized treatment for the most aggressive forms of breast cancer, having developed novel management strategies based on an understanding of the altered genes in individual patients. She stresses comprehensive risk reduction and prevention strategies in high-risk populations, as well as earlier detection through advanced imaging technologies.

View Details

Guest: Robert C. Young, MD

Host: Matt Birnholz, MD

The American Society of Clinical Oncology (ASCO) Conference brings over 30,000 people each year and has a membership of over 33,000, a third of which are international. Discussing important clinical research updates unveiled at this event by scientists from across the world is Dr. Robert C. Young, President of RCY Medicine in Philadelphia and past-President of ASCO. Dr. Young was also awarded ASCO's Distinguished Service Award for Scientific Leadership in 2004.

View Details

Guest: Alan Astrow, MD

Host: Leslie P. Lundt, MD

All the technology and advances in medical science hasn't changed the most difficult thing we do as physicians - relay emotionally charged diagnostic and prognostic information to our patients. How can we do a better job? Communication skills do not automatically improve with increasing physician experience. Dr. Alan Astrow, the director of the division of hematology and medical oncology at Maimonides Cancer Center in New York City explains how we can break bad news to patients in a more effective and supportive way.